Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Hodge

Surgery Johnson City, TN Medical Doctor

NPI 1588641187 CMS profile 71676

2333 Knob Creek Rd Ste 16, Johnson City, TN 37604

Open in the dashboard

General payments

$14,040

112 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Hodge of Johnson City, TN is reported in the CMS Open Payments database as having received $14,040 across 112 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,743 18
2024 General $738 11
2023 General $4,583 31
2022 General $860 11
2021 General $384 5
2020 General $13 1
2019 General $5,719 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Hodge
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Michael Hodge were reported at $1,743. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Michael Hodge Surgery median Middle half National median
2019 $5,719 $253 $82–$1,521 $163
2020 $13 $131 $40–$706 $114
2021 $384 $168 $50–$904 $132
2022 $860 $224 $76–$1,218 $149
2023 $4,583 $253 $82–$1,255 $160
2024 $738 $279 $90–$1,381 $164
2025 $1,743 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $8,292 54 payments
  2. Intuitive Surgical, Inc. $3,751 37 payments
  3. Stryker Corporation $1,402 5 payments
  4. CONMED Corporation $269 4 payments
  5. PolyNovo North America LLC $53 1 payment
  6. Innovation Technologies Inc $50 1 payment
  7. Ethicon US, LLC $38 2 payments
  8. Boston Scientific Corporation $32 1 payment
  9. Endogastric Solutions, Inc $31 1 payment
  10. Takeda Pharmaceuticals U.S.A., Inc. $29 1 payment
  11. Other $92 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $8,444 26 payments
  2. Food and Beverage $5,596 86 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $3,751 37 payments
  2. GORE BIO-A Tissue Reinforcement $3,675 22 payments
  3. BIO-A Tissue Reinforcement $2,358 12 payments
  4. SEAMGUARD $869 8 payments
  5. XIA $515 2 payments
  6. 1688 $514 1 payment
  7. SEAMGUARD Staple Line Reinforcement $371 7 payments
  8. SEAMGUARD Bioabsorbable Staple Line Reinforcement $367 2 payments
  9. AIRSEAL $269 4 payments
  10. SPY-PHI SYSTEM $243 1 payment
  11. Other $1,122 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

232

Median for General Surgery: 59

Drug cost

$4,464

Median for General Surgery: $393

Branded share of claims

60.8%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 30 $1,845
Omeprazole Generic 32 $879
Erythromycin Erythromycin Base Brand 12 $451
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 70 $445
Procto-Med Hc Hydrocortisone Brand 15 $294
Hydrocortisone Generic 20 $248
Ondansetron Odt Ondansetron Brand 14 $115
Metoclopramide Hcl Generic 24 $105
Neomycin Sulfate Generic 15 $83

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 108 billing codes

Paid by Medicare

$89,750

Medicare's payments for the services billed

Medicare patients

248

Average age 72

Services billed

591

125 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 40%
Diabetes 37%
Chronic kidney disease 35%
Depression 35%
COPD 25%
Cancer 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

112 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record